作者
Michael J Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz-Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Rebecca A Moss, Jean-Marie Ledeine, Z Alexander Cao, Shital Kamble, Scott Kopetz, Thierry André
发表日期
2018/3/10
期刊
Journal of clinical oncology
卷号
36
期号
8
页码范围
773-779
出版商
American Society of Clinical Oncology
简介
Purpose
Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previously treated patients with DNA mismatch repair–deficient (dMMR)/microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC); nivolumab plus ipilimumab may improve these outcomes. Efficacy and safety results for the nivolumab plus ipilimumab cohort of CheckMate-142, the largest single-study report of an immunotherapy combination in dMMR/MSI-H mCRC, are reported.
Patients and Methods
Patients received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg once every 3 weeks (four doses) followed by nivolumab 3 mg/kg once every 2 weeks. Primary end point was investigator-assessed ORR.
Results
Of 119 patients, 76% had received ≥ two prior systemic therapies. At median follow-up of 13.4 months, investigator-assessed …
学术搜索中的文章
MJ Overman, S Lonardi, KYM Wong, HJ Lenz… - Journal of clinical oncology, 2018